Corporate Profile

We are a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders.

Our initial focus is on developing our novel and proprietary 5-Methoxy-N,N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment Resistant Depression, or TRD.

Our lead product candidate, GH001, is formulated for 5-MeO-DMT administration via a proprietary inhalation approach. With GH001, we have completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). Based on the observed clinical activity, where 87.5% of patients with TRD were brought into an ultra-rapid remission with our GH001 individualized single-day dosing regimen in the Phase 2 part of the trial, we believe that GH001 has potential to change the way TRD is treated today.

Our portfolio also includes GH002 and GH003, our proprietary injectable and intranasal 5-MeO-DMT product candidates.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

SEC Filings

Filing date Description Form

Amendment to a previously filed 20-F

20-F/A

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act

6-K

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act

6-K